Patients’ disease must not have micropapillary components
Patient has a known hypersensitivity to any of the components of the study drug
Known hypersensitivity to any of the components of nal-IRI, other liposomal products, fluoropyrimidines or leucovorin
Known hypersensitivity to the components of MM-310, or docetaxel
Known hypersensitivity to any of the components of RO6874281
For Part B exclusively, known hypersensitivity to any of the components of trastuzumab
For Part C exclusively, known hypersensitivity to any of the components of cetuximab
Known allergy, hypersensitivity, or contraindication to paclitaxel, docetaxel, or irinotecan or any components used in their preparation
Patients with known hypersensitivity to any of the components of CBL0137;
Known hypersensitivity to the components of niraparib components or their formulation excipients
Known hypersensitivity to ferumoxytol or any of its components
History of, or known, hypersensitivity to any components of melphalan or the components of the Melphalan/HDS system.
Prior hypersensitivity to any of the components of the study drugs
Any known hypersensitivity or contraindication to the components of the study drug AZD1775
No known hypersensitivity or contraindication to the components of study treatment (M6620 [VX-970], gemcitabine)
Any known hypersensitivity or contraindication to the components of the study drug AZD1775
Known hypersensitivity to any of the components of the study drugs
Known hypersensitivity to any of the components of M7824 or eribulin.
Known hypersensitivity to any of the components of LMB-100 and/or SEL-110
Known hypersensitivity to any of the components of cabozantinib or nivolumab
Participants with prior use of pirfenidone or known hypersensitivity to any of the components of study treatment will be excluded from the study
History of hypersensitivity to Vicinium or its components
Patients must not have a known hypersensitivity to the components of niraparib or the excipients
Patient with documented hypersensitivity to any of the components of the therapy program
Known hypersensitivity to the components of study drugs, its analogs, or drugs of similar chemical or biologic composition.
A known allergy or history of hypersensitivity to silicon, phosphorous or any of the OncoSil™ components
Patients with a known history of hypersensitivity to lomustine, dacarbazine, or any components of lomustine
Patient has known hypersensitivity to the components of the study drugs or any analogs
Patient has known hypersensitivity to the components of the study drugs or their analogs
Known hypersensitivity to any of the components of LMB-100
Known hypersensitivity to any of the components of LMB-100
Known hypersensitivity to the components of study drugs, its analogs, or drugs of similar chemical or biologic composition
Known hypersensitivity reactions to any of the components of Sym004
Patients with known allergy or hypersensitivity to selinexor, sorafenib or any of its components
Patients with known hypersensitivity to the components of the study drugs or their analogs
Patients with known allergy or hypersensitivity to nivolumab, ipilimumab, 5-azacytidine, or any of their components
Patients with documented hypersensitivity to any components of the study program
Patient with documented hypersensitivity to any of the components of the chemotherapy program
Patients with known hypersensitivity to any of the components of PFK-158.
Known hypersensitivity to any of the components of MM-398 or other liposomal products
Tumor with ?25% IDC components
Patients with known allergy or hypersensitivity to quizartinib, mannitol, AZA, cytarabine or any of their components.
Patient has known hypersensitivity to the components of study drug or its analogs
Patients with known hypersensitivity to the components of study drug or its analogs
Patient with documented hypersensitivity to any of the components of the chemotherapy program
Known hypersensitivity to enzalutamide or any of its components.
Patients with a history of or known hypersensitivity to melphalan or the components of the Melphalan/HDS system.
Have a history of hypersensitivity reaction to any of the components of Temozolomide
Has known hypersensitivity to TAS-119 or its components.
Has known hypersensitivity to Cremophor® EL, paclitaxel or its components.
Any known hypersensitivity or contraindication to the components of the study drug AZD1775
Any known hypersensitivity or contraindication to the components of the study drug AZD1775 or olaparib.
Known hypersensitivity to the components of study drugs or analogs of study drugs
Patient with documented hypersensitivity to any of the components of the chemotherapy program
Known hypersensitivity to any components of study drugs
Have a known hypersensitivity to any of the components of AG-120, matched placebo, or azacitidine.
Known hypersensitivity to any of the components of tazemetostat
Known hypersensitivity to any of the products used in the trial-G-CSF (Neupogen), plerixafor, or any planned components of conditioning regimens
Known documented or suspected hypersensitivity to the components of the study drug(s) or analogs
Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C
Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C
Known hypersensitivity to any of the components of RO6958688 and/or obinutuzumab
Hypersensitivity to ASTX660, excipients of the drug product, or other components of the study treatment regimen.
Known hypersensitivity to any of the components of niraparib or prior hypersensitivity reactions to that class of drugs.
Known hypersensitivity reaction to temozolomide or any of its components, or dacarbazine (DTIC) if enrolled on ARM 1 or irinotecan or any of its components if enrolled on ARM 2
Known hypersensitivity to any of the GTx-024 components or subjects previously received treatment with SARM
Has known hypersensitivity to any of the components of IP.
Subject has known hypersensitivity to immunoglobulins or any of the products or components to be administered during dosing.
Known hypersensitivity to any of the components of MM-398, other liposomal products, fluoropyrimidines or leucovorin
Known hypersensitivity to the components of the study therapy or its analogs.
have a known allergy or hypersensitivity reaction to any of the treatment components
Have a known allergy or hypersensitivity reaction to any of the treatment components.
Patients who are known sensitive to any of the products or components to be administered during treatment with talimogene laherparepvec
Patients with known allergy or hypersensitivity to lirilumab, 5-azacytidine, or any of their components; patients who have previously been treated with lirilumab in combination with 5-azacytidine will be excluded
Known serious reactions or hypersensitivity to any components of the UV1 vaccine or similar peptide based vaccines
Known hypersensitivity to the components of niraparib
Known prior severe allergic/hypersensitivity to the chemotherapy or any of the components of the study treatment
Subjects with known hypersensitivity to any of the components of AG-120.
Subjects with known hypersensitivity to any of the components of AG-221.
Known hypersensitivity to any components of the treatments
Patients with a known hypersensitivity to any of the components of the drug products
Patients with previous hypersensitivity reactions to the study drugs and components (ex: podophyllum and povidone).
Hypersensitivity to one or more of the TL-118 active components
History of hypersensitivity reactions to any components of the treatment regimen
Any known hypersensitivity to ofatumumab or its components.
Patient has known hypersensitivity to the components of study drug or its analogs
Patients with a known hypersensitivity to any of the components of the drug products
Has a known hypersensitivity to the components of the study treatment or its analogs.
Known hypersensitivity to cyclophosphamide, its metabolites or any other components, or known urinary outflow obstruction.
Patient has a known hypersensitivity to the components of study drugs, its analogues, or drugs of similar chemical or biologic composition
Known hypersensitivity to any of the components of RO6927005
Patients with known hypersensitivity to any components of ME-344 or topotecan study drug product
Any known hypersensitivity or contraindication to the components of study treatment
Patient has hypersensitivity to any of the components of study drugs.
Patients with known hypersensitivity to any of the components of AN-152 including doxorubicin and LH-RH agonists
Subjects with known hypersensitivity to any components of ALKS 4230
Subjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only)
Known hypersensitivity to any of the treatment components of ramucirumab or LY2875358.
Known hypersensitivity to the components of niraparib
Patient has a known hypersensitivity to any of the components of the study drug.
Known hypersensitivity to HDAC inhibitors or to any of the components of mocetinostat
Known hypersensitivity to any of the components of AG-221
Known hypersensitivity to any components of the study drugs
Patients with known hypersensitivity to any of the components of romidepsin or who have had hypersensitivity reactions to paclitaxel
Patients with a known or suspected hypersensitivity to any of the components of OTS167.
Known hypersensitivity to any components of SC16LD6.5 study drug product.
Known significant hypersensitivity to any components of study treatment
Patients with a known or suspected hypersensitivity to either gemcitabine or any of the components of PRI-724.
Hypersensitivity of AT13387 or other components of the drug product
Known hypersensitivity to the components of niraparib, PD-1 inhibitor, or their excipients
Known hypersensitivity to the components of niraparib or excipients
Known hypersensitivity to any of the components of PRI-724
Patients with a known hypersensitivity to any of the components of the drug products
History of allergies or known hypersensitivity to any components of melphalan or the components of the Melphalan/HDS system
Patients with known allergy or hypersensitivity to ponatinib, or 5-azacytidine, or any of their components
Patient with known hypersensitivity to rocuronium, sugammadex or its components.
Participants with known hypersensitivity to modafinil, armodafinil, or any of its components
Patients with previous history of hypersensitivity to ribavirin or its components
Have known hypersensitivity or allergy to eggs, egg or chicken protein, or other components of the study vaccine
History of hypersensitivity to ribociclib or any of its components
Patients with hypersensitivity to sonazoid or one of its components
Hypersensitivity to CBT-101, excipients of the drug product, or other components of the study treatment regimen.
Known hypersensitivity to the study drug or components of the preparation
Known hypersensitivity to Feraheme (ferumoxytol) or any of its components
Any known hypersensitivity or contraindication to the components of study treatment
Patients with known hypersensitivity to any of the components of PEGPH20 or cetuximab*
Patients may not have a known hypersensitivity to any of the components of ganetespib
Known hypersensitivity to any oligodeoxynucleotide.
Known hypersensitivity to any of the study drugs
Known hypersensitivity to thalidomide.
Known hypersensitivity to any of the study drugs
Known hypersensitivity to any of the study drugs
Known hypersensitivity to any of the study drugs or analogs
Patients with known prior hypersensitivity reaction to any of the study drugs
Known hypersensitivity to any of the study drugs
Known hypersensitivity to study drugs;
Known hypersensitivity to one or more of the study agents
Known hypersensitivity to any of the study drugs or analogs
Known hypersensitivity to the study drugs or the drugs with similar chemical structures
Known hypersensitivity to one or more of the study agents
Known hypersensitivity to the trial drugs (volasertib and romidepsin)
Known hypersensitivity to any of the study drugs
Known hypersensitivity to one or more of the study agents
Known hypersensitivity to thalidomide
Prior use of gossypol or AT-101, or known hypersensitivity to gossypol or AT-101
Known hypersensitivity to thalidomide
Patients with a known hypersensitivity to any of the study agents
Known hypersensitivity to thalidomide.
Known allergy or hypersensitivity to any of the study drugs
Known hypersensitivity to any of the study agents
Known hypersensitivity to thalidomide
Known hypersensitivity to thalidomide or rituximab
Known hypersensitivity to one or more of the study agents
Patients with known hypersensitivity to any oligodeoxynucleotide.
Known hypersensitivity to any of the study drugs
Known hypersensitivity to thalidomide
Known hypersensitivity to any of the study drugs
Known anaphylactic or severe hypersensitivity to the study drugs or their analogs
Known hypersensitivity to thalidomide
Known anaphylactic or severe hypersensitivity to study drugs or their analogs
Known hypersensitivity to thalidomide
Known hypersensitivity to thalidomide.
Known hypersensitivity to any of the study agents
Any contraindication or known allergy or hypersensitivity to any study drugs
Patient has known hypersensitivity to thalidomide
Known hypersensitivity to thalidomide
Known hypersensitivity to thalidomide
Known hypersensitivity to any of the study drugs
Known hypersensitivity to any of the study drugs involved
Known hypersensitivity to thalidomide or other immunomodulatory drugs.
Known hypersensitivity to thalidomide
Known hypersensitivity to the study drugs
Known hypersensitivity to the study drugs
Known hypersensitivity to polymyxin B
Known hypersensitivity to any of the study drugs
Have known hypersensitivity to pancuronium bromide, atracurium or cisatracurium,
Any known hypersensitivity to dexmedetomidine
Known hypersensitivity to one or more of the study agents
